Doxorubicin Recruiting Phase 2 / 3 Trials for Ovarian Undifferentiated Carcinoma / Ovarian Endometrioid Adenocarcinoma / Recurrent Ovarian Carcinoma / Fallopian Tube Undifferentiated Carcinoma / Fallopian Tube Clear Cell Adenocarcinoma / Ovarian Serous Adenocarcinoma / Ovarian Seromucinous Carcinoma / Recurrent Primary Peritoneal Carcinoma / Malignant Ovarian Mixed Epithelial Tumor / Ovarian Clear Cell Adenocarcinoma / Primary Peritoneal Serous Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Undifferentiated Ovarian Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Fallopian Tube Serous Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Ovarian Mucinous Adenocarcinoma / Deleterious BRCA1 Gene Mutation / Recurrent Fallopian Tube Carcinoma / Deleterious BRCA2 Gene Mutation / Fallopian Tube Transitional Cell Carcinoma / Ovarian Transitional Cell Carcinoma Treatment